Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15457685 | 0.86 | PDK2 (0.52) | PDK2PDK4PGRMEN1KMT2A | |
| SCHEMBL5008650 | 0.83 | PGR (0.47) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL22643833 | 0.83 | MEN1 (0.47) | PDK2PDK4PGRMEN1KMT2A | |
| SCHEMBL23612470 | 0.81 | KMT2A (0.51) | PDK2PDK4PGRMEN1KMT2A | |
| SCHEMBL22279969 | 0.79 | HPGD (0.48) | PDK2PDK4PGRMEN1KMT2A | |
| SCHEMBL22643827 | 0.79 | PGR (0.49) | PGRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL24026026 | 0.77 | PGR (0.51) | PGRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22643832 | 0.77 | PGR (0.51) | PGRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22643834 | 0.76 | PGR (0.52) | PGRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2007119 | 0.76 | CYP1A2 (0.66) | PDK2PDK4PGRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PDK2 2734/4885PDK4 2495/4885PGR 1299/4885 |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | PDK2 1907/4885PDK4 1116/4885PGR 2539/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | PDK2 4448/4885PDK4 4609/4885PGR 2406/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PDK2 2734/4885PDK4 2495/4885PGR 1299/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | PDK2 976/4885PDK4 1636/4885PGR 3243/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | PDK2 2666/4885PDK4 2435/4885PGR 1006/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | PDK2 4448/4885PDK4 4609/4885PGR 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.